ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Sleep Aid Has Antituberculosis Activity


Ambien’s imidazo scaffold makes good starting point for finding novel antituberculosis agents

by Celia Henry Arnaud
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

Zolpidem, better known as the sleep aid Ambien, is structurally similar to imidazo compounds that are promising antituberculosis agents. Marvin J. Miller of the University of Notre Dame and coworkers decided to see whether zolpidem also has anti-TB properties (ACS Infect. Dis. 2014, DOI: 10.1021/id500008t). Zolpidem itself is a mediocre inhibitor with, at best, a minimum inhibitory concentration (MIC) of 10 μM. But when the chemists rearranged the pieces of zolpidem into structural isomers, the MICs improved greatly, with one compound having an MIC of 0.004 μM. The researchers further elaborated the isomers into a series of analogs. In all, the team tested a total of 15 compounds against clinically relevant strains of drug-sensitive, multi-drug-resistant, and extensively drug-resistant Mycobacterium tuberculosis. Assays with a variety of microbes reveal that the compounds are selective for M. tuberculosis. So far, the compounds have been tested in cell lines but not in animal models. Studies to select optimal compounds are ongoing with scientists at Notre Dame, the pharmaceutical company Eli Lilly & Co., and the Infectious Disease Research Institute in Seattle, Miller says.

X

Article:

This article has been sent to the following recipient:

Comments
Richard Cox (January 15, 2015 6:20 PM)
It would be appropriate to mention the contribution of Mr. Garrett Moraski, Dr. Miller's longtime collaborator, and Hsiri Therapeutics, the company working to commercialize those imidazopyridines developed at Notre Dame.
Richard Cox
Director, University of Notre Dame Office of Technology Transfer

Leave A Comment

*Required to comment